MARLBOROUGH, Mass. and SAN MATEO, Calif.--(BUSINESS WIRE)--Xcellerex, Inc. and Itero Biopharmaceuticals, Inc. announced today that they have signed a Letter of Intent to enter into a strategic collaboration for the production of Itero’s lead product, an undisclosed commercially differentiated therapeutic protein. Itero will initiate technology transfer for the product to Xcellerex immediately. Xcellerex will provide development expertise and product manufacturing for global clinical and commercialization supplies under the terms of a Master Services Agreement to be executed as soon as is reasonably practicable. The parties anticipate that this will be a multi-product collaboration, and for the first product, Xcellerex will manufacture Itero’s Phase 3 clinical materials in 2010/2011.
